{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:33:28Z","timestamp":1792679608401,"version":"4.5.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T00:00:00Z","timestamp":1558828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.biopsych.2019.05.012","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T13:48:49Z","timestamp":1558532929000},"page":"502-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence"],"prefix":"10.1016","volume":"86","author":[{"given":"Samuel David","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Abi-Dargham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2019.05.012_bib1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tips.2010.05.004","article-title":"Signaling pathways in schizophrenia: emerging targets and therapeutic strategies","volume":"31","author":"Karam","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2019.05.012_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1176\/jnp.6.4.348","article-title":"Working memory dysfunction in schizophrenia","volume":"6","author":"Goldman-Rakic","year":"1994","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2019.05.012_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.biopsych.2005.01.003","article-title":"Defining a cognitive function decrement in schizophrenia","volume":"57","author":"Keefe","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2019.05.012_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharmthera.2009.05.006","article-title":"30 years of dynorphins\u2014New insights on their functions in neuropsychiatric diseases","volume":"123","author":"Schwarzer","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: Drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2019.05.012_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2018.1459564","article-title":"Pharmacodynamic and pharmacokinetic evaluation of buprenorphine\u00a0+ samidorphan for the treatment of major depressive disorder","volume":"14","author":"Ragguett","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib9","first-page":"4","article-title":"Major depressive disorder and kappa opioid receptor antagonists","volume":"1","author":"Li","year":"2016","journal-title":"Transl Perioper Pain Med"},{"key":"10.1016\/j.biopsych.2019.05.012_bib10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/da.22500","article-title":"Kappa-opioid antagonists for psychiatric disorders: From bench to clinical trials","volume":"33","author":"Carlezon","year":"2016","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.biopsych.2019.05.012_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/npp.2017.205","article-title":"Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence","volume":"43","author":"Reed","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0010-440X(71)90031-9","article-title":"Cyclazocine treatment of opiate dependence: A progress report","volume":"12","author":"Resnick","year":"1971","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000468200","article-title":"A\u00a0controlled comparison of cyclazocine and naloxone treatment of the paroled narcotic addict","volume":"10","author":"Hanlon","year":"1975","journal-title":"Int Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib14","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(25)24372-5","article-title":"Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo","volume":"238","author":"Kumor","year":"1986","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1126\/science.351804","article-title":"Effects of naloxone on schizophrenia: Reduction in hallucinations in a subpopulation of subjects","volume":"201","author":"Watson","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2019.05.012_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/cpt196892215","article-title":"Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone","volume":"9","author":"Jasinski","year":"1968","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by k opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2019.05.012_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/j.1552-4604.1994.tb01991.x","article-title":"Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans","volume":"34","author":"Reece","year":"1994","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00002826-199310000-00007","article-title":"Dynorphin agonist therapy of Parkinson's disease","volume":"16","author":"Giuffra","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(00)80187-7","article-title":"Aquaretic effects of niravoline, a \u03ba-opioid agonist, in patients with cirrhosis","volume":"32","author":"Gadano","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130100788","article-title":"Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans","volume":"157","author":"Walsh","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","article-title":"A\u00a0review of the properties of spiradoline: A potent and selective k-opioid receptor agonist","volume":"9","author":"Wadenberg","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.biopsych.2019.05.012_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1527-3458.2005.tb00270.x","article-title":"Bremazocine: A \u03ba-opioid agonist with potent analgesic and other pharmacologic properties","volume":"11","author":"Dortch-Carnes","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.biopsych.2019.05.012_bib24","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: A potent naturally occurring nonnitrogenous \u03ba opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2019.05.012_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00213-011-2470-6","article-title":"Acute and post-acute behavioral and psychological effects of salvinorin A in humans","volume":"220","author":"Addy","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","article-title":"Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects","volume":"226","author":"MacLean","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib27","doi-asserted-by":"crossref","first-page":"pyw016","DOI":"10.1093\/ijnp\/pyw016","article-title":"Naltrexone but not ketanserin antagonizes the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans","volume":"19","author":"Maqueda","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bmj.1.6111.481","article-title":"Effects of naloxone on auditory hallucinations","volume":"1","author":"Orr","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.biopsych.2019.05.012_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0447.1982.tb00858.x","article-title":"Naloxone-induced reduction of schizophrenic symptoms: A case report","volume":"65","author":"J\u00f8rgensen","year":"1982","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2019.05.012_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF01250276","article-title":"Naloxone-induced reversal of schizophrenic hallucinations","volume":"40","author":"Gunne","year":"1977","journal-title":"J\u00a0Neural Transm (Vienna)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.325650","article-title":"Intravenous naloxone administration in schizophrenia and affective illness","volume":"197","author":"Davis","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2019.05.012_bib32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.860138","article-title":"Naloxone in chronic schizophrenia","volume":"196","author":"Volavka","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2019.05.012_bib33","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1176\/ajp.134.8.926","article-title":"Lack of effect on naloxone on schizophrenic symptoms","volume":"134","author":"Janowsky","year":"1977","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib34","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1176\/ajp.134.12.1408","article-title":"The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride","volume":"134","author":"Kurland","year":"1977","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0140-6736(79)92247-5","article-title":"Naloxone in schizophrenia: Negative result","volume":"313","author":"Lipinski","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2019.05.012_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S0033291700052223","article-title":"Lack of effect of naloxone and schizophrenic auditory hallucinations","volume":"11","author":"Freeman","year":"1981","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2019.05.012_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0028-1094547","article-title":"Indication of an antipsychotic action of the opiate antagonist naloxone","volume":"10","author":"Emrich","year":"1977","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(02)02872-8","article-title":"Naloxone displacement at opioid receptor sites measured in\u00a0vivo in the human brain","volume":"459","author":"Melichar","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/schbul\/9.2.213","article-title":"Narcotic antagonists in schizophrenia: A methodological review","volume":"9","author":"Mueser","year":"1983","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2019.05.012_bib40","series-title":"Neuro-Psychopharmacology: Proceedings of the 11th Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Vienna, July 9\u201314, 1978","first-page":"535","article-title":"Beta-endorphins and naloxone in psychiatric patients: Clinical and biological effects","author":"Lehmann","year":"1979"},{"key":"10.1016\/j.biopsych.2019.05.012_bib41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1176\/ajp.138.7.913","article-title":"The effects of naloxone in chronic schizophrenia","volume":"138","author":"Berger","year":"1981","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1983.tb06740.x","article-title":"Naloxone treatment for five days ineffective in schizophrenia","volume":"67","author":"Naber","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2019.05.012_bib43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/FTD.0b013e3181816214","article-title":"Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers","volume":"30","author":"Dowling","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.biopsych.2019.05.012_bib44","first-page":"527","article-title":"Studies on a possible pathological significance of endorphins in psychiatric disorders","author":"Emrich","year":"1979","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(82)90047-6","article-title":"Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects","volume":"7","author":"Kleinman","year":"1982","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0006-3223(85)90030-7","article-title":"High-dose naloxone administration in chronic schizophrenia","volume":"20","author":"Cohen","year":"1985","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib47","series-title":"Neural Peptides and Neuronal Communication","author":"Emrich","year":"1980"},{"key":"10.1016\/j.biopsych.2019.05.012_bib48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1192\/bjp.138.6.501","article-title":"A\u00a0study of naloxone with schizophrenic and manic patients","volume":"138","author":"Sethi BB Prakash","year":"1981","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2007-1017446","article-title":"Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients","volume":"16","author":"Naber","year":"1983","journal-title":"Pharmacopsychiatria"},{"key":"10.1016\/j.biopsych.2019.05.012_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0165-1781(84)90046-5","article-title":"Repeated naloxone administration in schizophrenia","volume":"12","author":"Verhoeven","year":"1984","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1982.04290030047009","article-title":"Short-term naloxone administration in schizophrenic and manic patients: A World Health Organization collaborative study","volume":"39","author":"Pickar","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib52","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-3223(89)90197-2","article-title":"Repeated naloxone administration in schizophrenia: a phase II World Health Organization study","volume":"25","author":"Pickar","year":"1989","journal-title":"Biol Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2019.05.012_bib53","article-title":"Naltrexone occupancy at kappa opioid receptors investigated in alcoholics by PET occupancy at kappa opioid receptors investigated in alcoholics by PET","volume":"58","author":"Vijay","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"part A","key":"10.1016\/j.biopsych.2019.05.012_bib54","doi-asserted-by":"crossref","first-page":"56A","DOI":"10.1097\/00002826-199201001-00031","article-title":"Naltrexone in chronic negative schizophrenia","volume":"15","author":"Marchesi","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib55","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0278-5846(95)00263-4","article-title":"The therapeutic role of naltrexone in negative symptom schizophrenia","volume":"19","author":"Marchesi","year":"1995","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib56","first-page":"1016","article-title":"Naltrexone augmentation of risperidone in treatment of schizophrenia symptoms: A randomized placebo-controlled study","volume":"2","author":"Tatari","year":"2014","journal-title":"Ann Psychiatry Ment Health"},{"key":"10.1016\/j.biopsych.2019.05.012_bib57","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1176\/ajp.134.12.1430","article-title":"An oral opiate antagonist in chronic schizophrenia: A pilot study","volume":"134","author":"Mielke","year":"1977","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib58","first-page":"909","article-title":"Trial of naltrexone in chronic-schizophrenia","volume":"22","author":"Simpson","year":"1977","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.biopsych.2019.05.012_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000468408","article-title":"Naltrexone in chronic schizophrenia","volume":"15","author":"Ragheb","year":"1980","journal-title":"International pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00431756","article-title":"Assessment of naltrexone\u00a0in the treatment of schizophrenia","volume":"74","author":"Gitlin","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib61","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00004714-199806000-00011","article-title":"Naltrexone augmentation of neuroleptics in schizophrenia","volume":"18","author":"Sernyak","year":"1998","journal-title":"Journal of clinical psychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib62","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1176\/ajp.144.10.1340","article-title":"Antipsychotic effect of buprenorphine in schizophrenia","volume":"144","author":"Schmauss","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hup.470060113","article-title":"Buprenorphine and schizophrenia","volume":"6","author":"Groves","year":"1991","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib64","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/npp.1993.49","article-title":"Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients","volume":"9","author":"Rapaport","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/schbul\/5.2.227","article-title":"Endorphins, dopamine, and schizophrenia","volume":"5","author":"Volavka","year":"1979","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2019.05.012_bib66","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-3223(85)90179-9","article-title":"Dopamine and the action of opiates: A reevaluation of the dopamine hypothesis of schizophrenia with special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia","volume":"20","author":"Schmauss","year":"1985","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib69","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/schbul\/14.2.157","article-title":"Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia","volume":"14","author":"Weinberger","year":"1988","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2019.05.012_bib70","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.1988.01800310013001","article-title":"Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism","volume":"45","author":"Weinberger","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib71","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/(SICI)1096-9861(19961223)376:4<530::AID-CNE3>3.0.CO;2-2","article-title":"Dynorphin regulates D1 dopamine receptor-mediated responses in the striatum: Relative contributions of pre-and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction","volume":"376","author":"Steiner","year":"1996","journal-title":"J\u00a0Comp Neurol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/syn.10005","article-title":"Major coexpression of \u03ba-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles","volume":"42","author":"Svingos","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2019.05.012_bib73","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ijnp\/pyx042","article-title":"Mechanisms of kappa opioid receptor potentiation of dopamine D2 receptor function in quinpirole-induced locomotor sensitization in ratsKOR potentiation of D2R-induced behavior","volume":"20","author":"Escobar","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainresrev.2009.09.008","article-title":"kappa-Opioid receptor signaling and brain reward function","volume":"62","author":"Bruijnzeel","year":"2009","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.biopsych.2019.05.012_bib75","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-3565(25)24578-5","article-title":"Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats","volume":"244","author":"Di Chiara","year":"1988","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib76","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1113\/JP274190","article-title":"Long-term plasticity of corticostriatal synapses is modulated by pathway-specific co-release of opioids through \u03ba-opioid receptors","volume":"595","author":"Hawes","year":"2017","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuron.2016.12.005","article-title":"Pathway-and cell-specific kappa-opioid receptor modulation of excitation-inhibition balance differentially gates D1 and D2 accumbens neuron activity","volume":"93","author":"Tejeda","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2019.05.012_bib78","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-3565(25)23043-9","article-title":"Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain","volume":"256","author":"Manzanares","year":"1991","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib79","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0022-3565(25)39324-9","article-title":"Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In\u00a0vivo microdialysis studies","volume":"266","author":"Devine","year":"1993","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","article-title":"U50, 488, a \u03ba opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats","volume":"181","author":"Maisonneuve","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2019.05.012_bib81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-3565(24)37186-1","article-title":"Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: An in\u00a0vivo fast-cyclic voltammetry study","volume":"284","author":"Xi","year":"1998","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib82","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1046\/j.1471-4159.1999.0731066.x","article-title":"The K-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum","volume":"73","author":"Gray","year":"1999","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.biopsych.2019.05.012_bib83","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/npp.2013.171","article-title":"Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion","volume":"38","author":"Chefer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib84","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-2999(94)00451-X","article-title":"Comparative effects of selective \u03ba-opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats","volume":"264","author":"Zaratin","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib85","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the \u03ba-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats","volume":"316","author":"Carlezon","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib86","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00213-004-2087-0","article-title":"Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors","volume":"179","author":"Zhang","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-007-1067-6","article-title":"Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum","volume":"197","author":"Gehrke","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib88","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jnr.20890","article-title":"Repeated administration of the selective kappa-opioid receptor agonist U-69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens","volume":"84","author":"Fuentealba","year":"2006","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib89","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/syn.20424","article-title":"Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa-opioid receptor agonist U-69593","volume":"61","author":"Fuentealba","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2019.05.012_bib90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.neuint.2012.01.014","article-title":"Repeated treatment with the kappa opioid receptor agonist U69593 reverses enhanced K (+) induced dopamine release in the nucleus accumbens, but not the expression of locomotor sensitization in amphetamine-sensitized rats","volume":"60","author":"Escobar Adel","year":"2012","journal-title":"Neurochem Int"},{"key":"10.1016\/j.biopsych.2019.05.012_bib91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1098-2396(199811)30:3<255::AID-SYN3>3.0.CO;2-A","article-title":"Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective \u03ba-opioid receptor agonist","volume":"30","author":"Heidbreder","year":"1998","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2019.05.012_bib92","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuropharm.2014.07.016","article-title":"Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1\/2-dependent mechanism","volume":"86","author":"Kivell","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib93","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008877-199308000-00014","article-title":"Environmental and behavioral components of sensitization induced by the dopamine agonist quinpirole","volume":"4","author":"Szechtman","year":"1993","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib94","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/sj.npp.1300938","article-title":"Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2\/D3 agonist quinpirole: Pre-and postsynaptic mechanisms","volume":"31","author":"Perreault","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib95","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00213-007-0855-3","article-title":"Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2\/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats","volume":"194","author":"Perreault","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib96","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.72.11.4376","article-title":"Brain receptors for antipsychotic drugs and dopamine: Direct binding assays","volume":"72","author":"Seeman","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2019.05.012_bib97","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2019.05.012_bib98","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib99","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.npp.1301108","article-title":"Occupancy of striatal and extrastriatal dopamine D 2 receptors by clozapine and quetiapine","volume":"31","author":"Kessler","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pnpbp.2013.07.006","article-title":"Are dopamine D2 receptors out of control in psychosis?","volume":"46","author":"Seeman","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib102","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pnpbp.2013.10.003","article-title":"Is schizophrenia a dopamine supersensitivity psychotic reaction?","volume":"48","author":"Seeman","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib103","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1037\/0735-7044.121.5.976","article-title":"Kappa-opioid receptor stimulation quickens pathogenesis of compulsive checking in the quinpirole sensitization model of obsessive-compulsive disorder (OCD)","volume":"121","author":"Perreault","year":"2007","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.biopsych.2019.05.012_bib104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neulet.2008.09.035","article-title":"Effects of salvinorin A on locomotor sensitization to D2\/D3 dopamine agonist quinpirole","volume":"446","author":"Beerepoot","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2019.05.012_bib105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/1098-2396(20010315)39:4<343::AID-SYN1018>3.0.CO;2-Q","article-title":"Modulation of pre-and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593","volume":"39","author":"Acri","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2019.05.012_bib106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(01)01194-3","article-title":"Effects of \u03ba-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission","volume":"426","author":"Collins","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib107","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00008877-200107000-00002","article-title":"Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity","volume":"12","author":"Collins","year":"2001","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib108","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1749-6632.2001.tb03558.x","article-title":"Modulation of the behavioral and neurochemical effects of psychostimulants by \u03ba-opioid receptor systems","volume":"937","author":"Shippenberg","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2019.05.012_bib109","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1038\/npp.2014.157","article-title":"Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in\u00a0vivo in the mouse nucleus accumbens","volume":"39","author":"Ehrich","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib110","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/npp.2015.226","article-title":"Relative timing between kappa opioid receptor activation and cocaine determines the impact on reward and dopamine release","volume":"41","author":"Chartoff","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib111","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0022-3565(25)21016-3","article-title":"Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs","volume":"246","author":"Werling","year":"1988","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib112","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/npp.2013.76","article-title":"Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion","volume":"38","author":"Tejeda","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib113","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-3565(25)10296-6","article-title":"Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats","volume":"264","author":"Bals-Kubik","year":"1993","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib114","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1073\/pnas.0511159103","article-title":"\u03ba opioids selectively control dopaminergic neurons projecting to the prefrontal cortex","volume":"103","author":"Margolis","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2019.05.012_bib115","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/syn.20808","article-title":"Repeated treatment with the \u03ba-opioid agonist U-69593 increases K+-stimulated dopamine release in the rat medial prefrontal cortex","volume":"64","author":"Fuentealba","year":"2010","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2019.05.012_bib116","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.biopsych.2005.02.030","article-title":"Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats","volume":"57","author":"Bortolato","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib117","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00213-010-1799-6","article-title":"The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat","volume":"210","author":"Tejeda","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib118","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.neuropharm.2007.09.002","article-title":"Effects of kappa opioid receptor agonists on attention as assessed by a 5-choice serial reaction time task in rats","volume":"53","author":"Shannon","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib119","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2019.05.012_bib120","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/1091581811418538","article-title":"Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats","volume":"30","author":"Braida","year":"2011","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib121","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/npp.2017.133","article-title":"\u03ba-Opioid receptor activation in dopamine neurons disrupts behavioral inhibition","volume":"43","author":"Abraham","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib122","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1476-5381.1990.tb12110.x","article-title":"CI-977, a novel and selective agonist for the \u03ba-opioid receptor","volume":"101","author":"Hunter","year":"1990","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib123","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3565(25)11117-8","article-title":"Pharmacologic activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys","volume":"261","author":"Davis","year":"1992","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2019.05.012_bib124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(92)90621-F","article-title":"The effect of the kappa-opioid receptor agonist CI-977 in a rat model of focal cerebral ischaemia","volume":"576","author":"Kusumoto","year":"1992","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0006-8993(93)90474-2","article-title":"Effect of the kappa-1 opioid agonist CI-977 on ischemic brain damage and cerebral blood flow after middle cerebral artery occlusion in the rat","volume":"629","author":"Mackay","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib126","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1460-9568.1993.tb00947.x","article-title":"Neuroprotective effect of the \u03c7-agonist enadoline (CI-977) in rat models of focal cerebral ischaemia","volume":"5","author":"Hayward","year":"1993","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2019.05.012_bib127","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0006-8993(93)91268-W","article-title":"Focal cerebral ischemia in the cat: Pretreatment with a kappa-1 opioid receptor agonist, CI-977","volume":"618","author":"Mackay","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-2999(96)00622-X","article-title":"U-50488H, a selective \u03ba-opioid receptor agonist, improves carbon monoxide-induced delayed amnesia in mice","volume":"315","author":"Hiramatsu","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib129","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1152\/jn.00855.2004","article-title":"Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons","volume":"93","author":"Margolis","year":"2005","journal-title":"J\u00a0Neurophysiol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2018.09.023","article-title":"Dynorphin\/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders","volume":"1713","author":"Tejeda","year":"2019","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib131","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","article-title":"Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment","volume":"62","author":"Crowley","year":"2015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib132","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00018-011-0844-x","article-title":"The dynorphin\/\u03ba-opioid receptor system and its role in psychiatric disorders","volume":"69","author":"Tejeda","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.biopsych.2019.05.012_bib133","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0165-1781(90)90001-L","article-title":"Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients","volume":"34","author":"Heikkil\u00e4","year":"1990","journal-title":"Psychiatry Res"},{"issue":"suppl","key":"10.1016\/j.biopsych.2019.05.012_bib134","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/0893-133X(95)00201-N","article-title":"Clinical and biological markers for outcome in schizophrenia: A review of a longitudinal follow-up study in Uppsala schizophrenia research project","volume":"14","author":"Lindstr\u00f6m","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2019.05.012_bib135","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0143-4179(85)90077-0","article-title":"Lower CSF level of dynorphin (1\u20138) immunoreactivity in schizophrenic patients","volume":"5","author":"Zhang","year":"1985","journal-title":"Neuropeptides"},{"key":"10.1016\/j.biopsych.2019.05.012_bib136","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1600-0447.1978.tb06883.x","article-title":"Endorphins in human cerebrospinal fluid: clinical correlations to some psychotic states","volume":"57","author":"Lindtr\u00f6m","year":"1978","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2019.05.012_bib137","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0140-6736(79)92769-7","article-title":"CSF \u03b2-endorphin in schizophrenia","volume":"313","author":"Domschke","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2019.05.012_bib138","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0165-1781(86)90001-6","article-title":"CSF levels of receptor-active endorphins in schizophrenic patients: Correlations with symptomalogy and monoamine metabolites","volume":"19","author":"Lindstr\u00f6m","year":"1986","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2019.05.012_bib139","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.472735","article-title":"Plasma beta-endorphin immunoreactivity in schizophrenia","volume":"205","author":"Ross","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2019.05.012_bib140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0165-0270(91)90040-7","article-title":"Analysis of laminar distribution of kappa opiate receptor in human cortex: comparison between schizophrenia and normal","volume":"36","author":"Royston","year":"1991","journal-title":"J\u00a0Neurosci Methods"},{"key":"10.1016\/j.biopsych.2019.05.012_bib141","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0361-9230(01)00525-1","article-title":"Prodynorphin and \u03ba opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders","volume":"55","author":"Peckys","year":"2001","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2019.05.012_bib142","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5498\/wjp.v5.i4.352","article-title":"Conceptualization and treatment of negative symptoms in schizophrenia","volume":"5","author":"Sarkar","year":"2015","journal-title":"World J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.05.012_bib143","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications","volume":"178","author":"Toll","year":"1998","journal-title":"NIDA Res Mongr"},{"key":"10.1016\/j.biopsych.2019.05.012_bib144","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","article-title":"Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence","volume":"35","author":"Gonzalez","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.biopsych.2019.05.012_bib145","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.biopsych.2019.05.012_bib146","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bcp.12805","article-title":"Population pharmacokinetics of nalmefene in healthy subjects and its relation to \u03bc-opioid receptor occupancy","volume":"81","author":"Kyhl","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2019.05.012_bib147","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/sj.npp.1300790","article-title":"Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing","volume":"30","author":"Ingman","year":"2005","journal-title":"Neuropsychopharmacology"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322319313794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322319313794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:02:57Z","timestamp":1762099377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322319313794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":147,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0006322319313794"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2019.05.012","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2019.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}